Retroperitoneal Liposarcoma, Soft Tissue Sarcoma
Conditions
Brief summary
The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease. Often, tumors recur in locations within the retroperitoneum remote from the original primary tumor. This study hypothesizes that normal appearing retroperitoneal fat actually harbors underlying genetic changes which predispose to development of future liposarcoma. To accomplish this goal, retroperitoneal fat is sampled from quadrants within and remote from the primary tumor and is subsequently subjected to genetic analyses looking for such predisposing factors.
Interventions
OTHERBiospecimen sample collection during standard-of-care surgery
Patients in this observational study are undergoing planned surgical resection of their retroperitoneal sarcoma as prescribed by their primary surgeon and treatment team. In addition to removal of the primary tumor, surgeons remove 4 samples of retroperitoneal fat and a sample of subcutaneous fat for further study at the time of the operation.
Sponsors
Fox Chase Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Adult patients (age ≥18 years). * Histologically confirmed retroperitoneal liposarcoma via preoperative biopsy, or cross-sectional imaging suspicious for liposarcoma with planned surgical resection * Will be undergoing surgical resection for treatment of primary or recurrent disease * Have provided informed consent to participate in this study
Exclusion criteria
• Prior surgical anatomy which makes sampling of remote areas of the retroperitoneum technically impossible or clinically undesirable for safety reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Presence of MDM2 amplification in normal retroperitoneal fat | Through study completion, an average of 3 years | MDM2 amplification of primary tumors and fat samples will be tested by immunohistochemistry and/or fluorescence in situ hybridization. |
Countries
United States
Contacts
Primary ContactAnthony Villano, MD
Outcome results
None listed